APLN and diabetic kidney disease: As an endogenous physiological regulator with antioxidative, anti-inflammatory and antiapoptotic properties, apelin is becoming a therapeutic target for kidney diseases, including renal ischemia-reperfusion injury (IRI), diabetic nephropathy, and renal fibrosis [14–16].